Bath Savings Trust Co Purchases 1,952 Shares of Zoetis Inc. (NYSE:ZTS)

Bath Savings Trust Co increased its position in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 9.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,874 shares of the company’s stock after acquiring an additional 1,952 shares during the quarter. Bath Savings Trust Co’s holdings in Zoetis were worth $4,317,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank acquired a new stake in Zoetis during the 4th quarter worth approximately $745,861,000. Morgan Stanley raised its holdings in Zoetis by 34.6% during the 4th quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock worth $1,593,395,000 after buying an additional 2,796,694 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in Zoetis by 124,281.9% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 2,332,160 shares of the company’s stock worth $341,778,000 after buying an additional 2,330,285 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Zoetis by 171.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,326,448 shares of the company’s stock worth $627,335,000 after buying an additional 2,102,306 shares during the period. Finally, Vaughan Nelson Investment Management L.P. acquired a new stake in Zoetis during the 3rd quarter worth approximately $176,219,000. Institutional investors own 89.47% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ZTS shares. Barclays lifted their price objective on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a report on Wednesday, February 14th. Jefferies Financial Group reiterated a “buy” rating and issued a $230.00 price objective on shares of Zoetis in a report on Tuesday, December 19th. Piper Sandler lifted their price objective on shares of Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a report on Tuesday, February 20th. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Finally, BNP Paribas started coverage on shares of Zoetis in a report on Thursday, December 7th. They issued an “outperform” rating and a $237.00 price objective on the stock. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $224.33.

Check Out Our Latest Stock Report on Zoetis

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the transaction, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.12% of the company’s stock.

Zoetis Price Performance

Shares of ZTS opened at $172.57 on Friday. The company has a market cap of $79.01 billion, a price-to-earnings ratio of 34.04, a PEG ratio of 2.69 and a beta of 0.87. Zoetis Inc. has a 1-year low of $151.03 and a 1-year high of $201.92. The company’s fifty day simple moving average is $190.23 and its 200 day simple moving average is $183.40. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTSGet Free Report) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same quarter in the previous year, the firm posted $1.15 earnings per share. Zoetis’s quarterly revenue was up 8.5% on a year-over-year basis. On average, research analysts forecast that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.00%. Zoetis’s dividend payout ratio (DPR) is 33.93%.

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.